$LH

LABCORP HOLDINGS INC.

Labcorp provides clinical laboratory testing and related services to healthcare providers, health plans, government programs, employers and patients, as well as laboratory and drug development services to pharmaceutical, biotechnology, medical device and diagnostic companies and contract research organizations. It operates two segments: Dx, which offers routine and specialty testing through laboratories and patient service sites across the U.S. and Canada, and Biopharma Laboratory Services (BLS), which provides early development research and central laboratory services for clinical trials worldwide. Labcorp earns money by billing responsible parties, including third-party payers, clients, Medicare and Medicaid, and patients, for clinical testing and related services. Consumers can also pay directly for tests purchased through Labcorp OnDemand. BLS provides drug development and clinical trial services to biopharma customers. Labcorp is headquartered in Burlington, North Carolina.

AlphAI earnings readthird quarter 2026 · OCT 28Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 GuidanceVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

3
2
2
—
$1.2M
Vaughn Bryan T
33%
See all $LH insider activity →
Low

Labcorp Earnings Call Signals Growth Despite PAMA Risks

Labcorp Holdings (LH) reported Q3 revenue of $3.8B, up 6.9% YoY, with adjusted EPS at $4.78. The company raised 2026 guidance, citing growth in diagnostics and biopharma services, but noted risks from proposed PAMA reimbursement cuts. Management highlighted strong backlog, productivity savings, and an active acquisition pipeline.

Myriad Genetics Earnings Call Signals Strategic Shift and Recovery

Myriad Genetics (MYGN) reported Q3 revenue of $202.7M, up 6% sequentially. Cancer Care revenue grew 1% YoY, while Prenatal Health declined 12%. Management highlighted improved margins and raised 2026 revenue guidance to $780M-$790M. The company plans to divest its Prenatal Health business to Labcorp for $210M, focusing on cancer testing.

Should Labcorp Stock Holders Look At Quest Diagnostics Instead?

Labcorp (LH) and Quest Diagnostics (DGX) both provide lab tests, but differ in additional services. Labcorp raised 2026 revenue guidance for its drug-development labs, while Quest increased its forecast due to testing volume growth. Both face Medicare fee cuts in 2027. Quest trades at lower trailing earnings multiple, grows faster, and has wider margins, but Labcorp is cheaper on sales and adjusted forecast earnings.

LH sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning LH (LABCORP HOLDINGS INC.). Coverage has skewed bullish: 3 bullish, 2 neutral, and 2 bearish.

Recent LH coverage spans financial news, earnings and mergers & acquisitions.

In the last 30 days, LH insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.2M). The most active reporter was Vaughn Bryan T, EVP and President, Diagnostics, with 1 filing. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving LH

AlphAI scores every news story that mentions LH with an AI model for sentiment and relevance, and aggregates insider trades from LABCORP HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LH

Score

Labcorp Earnings Call Signals Growth Despite PAMA Risks

Labcorp Holdings (LH) reported Q3 revenue of $3.8B, up 6.9% YoY, with adjusted EPS at $4.78. The company raised 2026 guidance, citing growth in diagnostics and biopharma services, but noted risks from proposed PAMA reimbursement cuts. Management highlighted strong backlog, productivity savings, and an active acquisition pipeline.

Should Labcorp Stock Holders Look At Quest Diagnostics Instead?

Labcorp (LH) and Quest Diagnostics (DGX) both provide lab tests, but differ in additional services. Labcorp raised 2026 revenue guidance for its drug-development labs, while Quest increased its forecast due to testing volume growth. Both face Medicare fee cuts in 2027. Quest trades at lower trailing earnings multiple, grows faster, and has wider margins, but Labcorp is cheaper on sales and adjusted forecast earnings.

Labcorp: 3 Key Takeaways for Long-Term Investors

Labcorp reported Q3 2026 revenue of $3.8B, up 7%, and raised full-year guidance. Medicare price cuts may reduce revenue by $125M in 2027, but the company plans to offset this through growth and cost efficiencies. Specialty testing and acquisitions are driving higher margins and volumes. Management remains optimistic about long-term profitability and growth.

$LHHighAI 9/10

Labcorp completes $375M Millennium Health takeover

Labcorp completed its $375M acquisition of Millennium Health, including $245M upfront and up to $130M in milestone payments. The deal aims to enhance Labcorp's toxicology services and expand its geographic reach. Millennium specializes in drug testing, complementing Labcorp's existing offerings. Labcorp CEO Adam Schechter highlighted the strategic fit and growth potential during an earnings call.

Labcorp Completes Millennium Health Deal as Quarterly Revenue Gains 6.9%

Labcorp completed its acquisition of Millennium Health, reporting a 6.9% revenue increase to $3.81 billion and a 14.5% rise in adjusted earnings per share for the quarter. The company raised its 2026 revenue growth outlook to 5.9%-6.7% and adjusted earnings per share guidance to $18.30-$18.70, higher than its July outlook. Labcorp also acquired MLM Medical Labs and signed deals for Myriad Genetics' prenatal testing business and BioReference Health assets.

Related tickers